Roivant Sciences Ltd. (ROIV)
↓ Download CSV- Sector Manufacturing
- Incorporated D0
- Fiscal year ends Mar 31
In fiscal 2026, Roivant Sciences Ltd. reported revenue of $8.26M, down 71.6% from the prior year. The company ran a net loss, with a net margin of -3629.2%. It held $5.71B in total assets against $416.27M in total liabilities.
Key ratios (FY2026)
-6235.7%
Operating margin
-3629.2%
Net margin
-5.7%
Return on equity
-71.6%
Revenue growth (YoY)
| Metric (FY) | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $8.26M | $29.05M | $32.71M | $31.53M | $55.29M | $23.80M | — |
| Operating Income | -$515.07M | -$1.00B | $4.50B | -$906.76M | -$1.35B | -$1.07B | — |
| Net Income | -$299.77M | -$171.98M | $4.35B | -$1.01B | -$845.26M | -$809.23M | — |
| EPS (Diluted) | $-0.54 | $-0.24 | $5.23 | $-1.42 | $-1.26 | — | — |
| Total Assets | $5.71B | $5.44B | $7.22B | $2.39B | $2.59B | $2.59B | — |
| Total Liabilities | $416.27M | $249.74M | $773.95M | $782.02M | $523.70M | $527.69M | — |
| Shareholders' Equity | $5.29B | $5.19B | $6.45B | $1.61B | $2.04B | $2.04B | $2.09B |
| Cash & Equivalents | $1.42B | $2.72B | $6.49B | $1.68B | $2.06B | $2.06B | — |
| Operating Cash Flow | -$750.35M | -$839.45M | -$765.27M | -$843.39M | -$677.73M | -$552.14M | — |
| Capital Expenditures | $8.21M | $4.60M | $1.38M | $12.69M | $17.44M | $5.81M | — |
| Shares Outstanding | 720.35M | 695.94M | 806.68M | 760.14M | 694.98M | 651.58M | — |